Mobile Menu
Deals & Transactions

Conyers advises Axovant Sciences Ltd. on its $315 million IPO

Conyers Dill & Pearman advised Axovant Sciences Ltd. on its highly successful underwritten initial public offering of 21,000,000 of its shares, including exercise in full of the greenshoe option, for a total fundraising of $315 million. Roivant Sciences Ltd., the parent company, retains 75% of the shares. This is thought to be the biggest New York IPO in the biotechnology sector for at least 20 years and it is the first New York biotech IPO to use a Bermuda company as the listing vehicle.

Robert Alexander, Carol Clarke and Neil Henderson from Conyers Bermuda worked on the matter.

 


Neil Henderson
Director

Bermuda   +1 441 298 7846



Accolades
_

"They understood the urgency and demanding nature of the deals that we were working on - they were very responsive and commercial, and worked with us to make it happen."
- Chambers Global